Myriad Genetics (MYGN) and Lumea have signed an agreement to integrate Myriad’s advanced molecular diagnostic tests – Prolaris Prostate Cancer ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and Lumea Inc., a leader in digital pathology solutions, have signed an agreement to ...

In a retrospective study of 265 patients with drug-resistant solid organ cancers, ‘Exacta AI’ provided at least seven therapy ...

Tempus AI (TEM) is soaring 13% today after investment bank TD Cowen reinstated coverage of the shares with a Buy rating. TEM ...

Wednesday, 2/5/2025 11:15 am-12:15 pm Gerstenzang 124 Molecular Genetics Journal Club (Engineering Faculty Search) Heidi Klumpe, PhD (Postdoctoral Fellow, Boston ...

Molecular detection methods may be used to ensure viral safety of blood products and to monitor food and environmental risk. HAV genetic diversity allows molecular epidemiology to be performed ...

Discovery of the molecular defects responsible for these diseases has initiated genetic diagnostics in many countries around the world, including the Middle East, Europe, USA, Japan and Australia.

Molecular genetic testing of asymptomatic children ... was already offering testing for MEFV mutations in UCLA's molecular diagnostic laboratory, was invited to join the group as a regular ...

Introduction to Newborn Screening InstrumentsNewborn screening is a critical medical process that involves testing newborns for certain genetic, metabolic, and congenital conditions. The objective is ...

Researchers at the University of Toronto have invented a new method that uses DNA sequencing to measure metabolites. This ...

However, current management is unstandardised and molecular diagnostic rates remain low, particularly in those with unilateral presentation. To further understanding of clinical and genetic management ...